BLK
BlackRock, Inc.
BLK has slightly lower modeled downside risk, despite its lower overall score.
CME
CME Group Inc.
CME has the edge over BLK overall, supported by stronger valuation and stronger modeled upside.
BLK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BLK's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BLK.
CME Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
CME's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CME.
BLK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $848 | -30% |
| Fair | 22x | $973 | -20% |
| Expensive | 26x | $1,149 | -5.5% |
| Current | 28x | $1,217 | — |
Historical ranges are pointers, not guarantees.
BLK's PE is in its expensive range at 28x.
CME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 24x | $289 | -8.3% |
| Forward | 24x | $316 | — |
| Fair | 26x | $314 | -0.4% |
| Current | 26x | $316 | — |
| Expensive | 33x | $405 | +28% |
Historical ranges are pointers, not guarantees.
CME has the edge over BLK in the historical PE scenario, which offers more potential upside but is not a forecast.
BLK Forward outlook
There aren't enough analyst estimates for BLK to show an outlook.
CME Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for CME, with profitability improving.
BLK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $43.87 | +11% |
| Q2 2026 | $41.73 | -0.4% |
| Q1 2026 | $39.73 | -4.7% |
| Q4 2025 | $35.31 | -17% |
| Q3 2025 | $39.42 | -2.7% |
| Q2 2025 | $41.89 | +4% |
| Q1 2025 | $41.69 | +5.9% |
| Q4 2024 | $42.53 | +16% |
BLK earned $43.87 per share over the past year, up 11% from the year before.
CME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.95 | +6.2% |
| Q3 2026 | $12.19 | +18% |
| Q2 2026 | $11.79 | +14% |
| Q1 2026 | $11.72 | +18% |
| Q4 2025 | $11.16 | +15% |
| Q3 2025 | $10.32 | +8.6% |
| Q2 2025 | $10.33 | +14% |
| Q1 2025 | $9.94 | +13% |
| Q4 2024 | $9.67 | +9.1% |
CME has the edge over BLK on earnings, with more consistent year-over-year improvement.
BLK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8B | +19% |
| Q2 2026 | $7.1B | +31% |
| Q1 2026 | $6.7B | +27% |
| Q4 2025 | $7B | +23% |
| Q3 2025 | $6.5B | +25% |
| Q2 2025 | $5.4B | +13% |
| Q1 2025 | $5.3B | +12% |
| Q4 2024 | $5.7B | +23% |
BLK has the edge over CME on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | 0 points |
| Q2 2026 | 35% | +2.8 points |
| Q1 2026 | 42% | +9.8 points |
| Q4 2025 | 24% | -13 points |
| Q3 2025 | 30% | -8.6 points |
| Q2 2025 | 32% | -5.5 points |
| Q1 2025 | 32% | -3.6 points |
| Q4 2024 | 37% | +2.3 points |
BLK's operating margin was 30% last quarter, about level with the same quarter a year ago, near the bottom of its range since 2019.
CME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7B | +13% |
| Q2 2026 | $1.7B | +0.8% |
| Q1 2026 | $1.9B | +14% |
| Q4 2025 | $1.6B | +8.1% |
| Q3 2025 | $1.5B | -3% |
| Q2 2025 | $1.7B | +10% |
| Q1 2025 | $1.6B | +10% |
| Q4 2024 | $1.5B | +6% |
CME's revenue has grown year over year for four quarters in a row: $1.7B last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +2.5 points |
| Q2 2026 | 65% | -1.8 points |
| Q1 2026 | 70% | +2.2 points |
| Q4 2025 | 62% | -0.3 points |
| Q3 2025 | 63% | -1.4 points |
| Q2 2025 | 67% | +1.4 points |
| Q1 2025 | 67% | +3 points |
| Q4 2024 | 62% | +2.1 points |
CME has the edge over BLK on profitability, with a higher operating margin.
BLK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6B | +95% |
| Q2 2026 | $1.1B | -12% |
| Q1 2026 | -$1.1B | +$120M |
| Q4 2025 | $2.1B | -15% |
| Q2 2025 | $1.3B | -6.1% |
| Q1 2025 | -$1.2B | -$734M |
| Q4 2024 | $2.5B | +35% |
| Q2 2024 | $1.4B | +47% |
BLK's free cash flow was $4.8B over the past year, up 22% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BLK.
CME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +13% |
| Q2 2026 | $923.5M | -11% |
| Q1 2026 | $1.2B | +12% |
| Q4 2025 | $1.1B | +11% |
| Q3 2025 | $949.7M | -2.4% |
| Q2 2025 | $1B | +37% |
| Q1 2025 | $1.1B | +26% |
| Q4 2024 | $991.7M | -3.1% |
CME's free cash flow was $4.3B over the past year, up 6.1% from the year before. Free cash flow isn't a meaningful measure for financial services companies like CME.
BLK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -148K shares |
| 1 year | -0.4% | -677K shares |
| 3 years | +9.3% | +14M shares |
| 5 years | +6.2% | +9.6M shares |
| Available history | +4.4% | +7M shares |
BLK has 165M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | $396M |
| Q1 2025 | $657M |
| Q4 2024 | $386M |
| Q2 2024 | $519M |
| Q1 2024 | $634M |
| Q4 2023 | $384M |
| Q3 2023 | $396M |
| Q2 2023 | $383M |
CME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -2.6M shares |
| 1 year | -0.5% | -1.8M shares |
| 3 years | -0.3% | -978K shares |
| 5 years | -0.1% | -347K shares |
| Available history | +0.1% | +402K shares |
CME has the edge over BLK on shareholder dilution, with a more favorable share count trend.
BLK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2024 | 0.2x | Very low |
| Q1 2024 | 0.3x | Very low |
| Q4 2023 | 0.1x | Very low |
BLK has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BLK.
CME Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2020 | -0.4x | Net Cash |
| Q2 2020 | -0.4x | Net Cash |
| Q1 2020 | -0.3x | Net Cash |
| Q4 2019 | -0.6x | Net Cash |
CME has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CME.
BLK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.5 | Neutral |
| Stochastic | 79.0 | Neutral |
BLK's weekly RSI is 64 (neutral) and its Stochastic is 79 (neutral).
CME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.2 | Neutral |
| Stochastic | 89.3 | Overbought |
CME's weekly RSI is 65 (neutral) and its Stochastic is 89 (overbought).
BLK PE vs Financial Services Sector
| Metric | BLK | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 13x | 113% above |
| PE % | 97 | 63 | 34 pts above |
BLK is trading at 28x earnings, a 113% premium to the Financial Services sector's median of 13x.
CME PE vs Financial Services Sector
| Metric | CME | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 13x | 99% above |
| PE % | 51 | 63 | 12 pts below |
CME has the edge over BLK on valuation relative to its sector.
BLK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,128.0 | 7.9% above |
| 20 week MA | $1,108.9 | 9.7% above |
| 50 week MA | $1,071.6 | 14% above |
| 100 week MA | $1,051.1 | 16% above |
| 200 week MA | $914.1 | 33% above |
BLK is in an uptrend: it's above all five of its weekly moving averages, and 33% above its 200-week average.
CME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $291.5 | 8.2% above |
| 20 week MA | $275.2 | 15% above |
| 50 week MA | $280.9 | 12% above |
| 100 week MA | $272.5 | 16% above |
| 200 week MA | $238.3 | 32% above |
CME is in an uptrend: it's above all five of its weekly moving averages, and 32% above its 200-week average.
BLK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $503.0 | $707.2 | +41% |
| 2021 | $707.2 | $913.9 | +29% |
| 2022 | $913.9 | $703.9 | -23% |
| 2023 | $703.9 | $811.8 | +15% |
| 2024 | $811.8 | $1,044.2 | +29% |
| 2025 | $1,044.2 | $1,088.1 | +4.2% |
| 2026 YTD | $1,088.1 | $1,216.6 | +12% |
BLK has finished higher in five of the last six years. It's up 12% so far in 2026.
CME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $202.8 | $178.5 | -12% |
| 2021 | $178.5 | $229.0 | +28% |
| 2022 | $229.0 | $173.3 | -24% |
| 2023 | $173.3 | $210.6 | +22% |
| 2024 | $210.6 | $233.5 | +11% |
| 2025 | $233.5 | $276.7 | +19% |
| 2026 YTD | $276.7 | $315.5 | +14% |
CME has the edge over BLK on returns for 2026, with the stronger performance.